Specialist Centre for Foot and Ankle Joint Surgery, Schön Clinic Munich-Harlaching, Munich, Germany.
Orthopaedics, Clinics Rechts der Isar of the Technical University of Munich, Germany.
Z Orthop Unfall. 2022 Aug;160(4):414-421. doi: 10.1055/a-1365-9655. Epub 2021 Mar 1.
The Cartiva implant (CI) is being increasingly used in the surgical therapy of hallux rigidus. Despite a growing number of studies, numerous questions regarding patient selection remain unanswered.
As part of a retrospective case series with prospective follow-up (average follow-up period: 12 months), a total of 44 patients (male/female = 16/28; mean age at the time of surgery: 55.4 years) with 44 CI were analysed (VAS, EFAS-, AOFAS-score). Using a correlation analysis and a machine learning algorithm, risk factors for therapy failure were investigated.
The overall survival rate of the CI was 93% at 12 months. The VAS, EFAS and AOFAS scores showed a significant improvement in comparison to the preoperative condition. The mobility of the metatarsophalangeal joint showed no increase. Patients with a medium osteoarthritis grade and a medium level of clinical restraint showed the greatest improvement in relation to their preoperative condition.
The CI can be seen as an effective therapy for hallux rigidus. Nonetheless, realistic patient expectations must be communicated.
Cartiva 植入物（CI）越来越多地被用于治疗拇僵硬。尽管研究越来越多，但仍有许多关于患者选择的问题尚未得到解答。
作为回顾性病例系列前瞻性随访的一部分（平均随访时间：12 个月），共分析了 44 例（男/女=16/28；手术时的平均年龄：55.4 岁）接受 44 例 CI 治疗的患者（VAS、EFAS、AOFAS 评分）。使用相关分析和机器学习算法，研究了治疗失败的风险因素。
CI 在 12 个月时的总体存活率为 93%。与术前相比，VAS、EFAS 和 AOFAS 评分均显著改善。跖趾关节的活动性没有增加。中等级别骨关节炎和中等程度临床限制的患者与术前相比，改善程度最大。
CI 可被视为治疗拇僵硬的有效方法。然而，必须与患者进行现实的期望沟通。
